Worth reading
9Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Items stated in the management plan
Publication date5 June 2026
This document does not state the plan name, plan period, or numerical targets.
Key initiatives
01Ongoing formation of Fund II and Fund III and expansion of the investment platform
02Selection of investment opportunities ahead of the full-scale launch of investment activities
03Building collaboration with 18 US venture capital firms for joint investments
04Due diligence on multiple investment opportunities
05We are working diligently toward executing investments
Plan assumptionsManagement fee rates vary by fund, but are generally around 2% per year, Performance fees are generally around 20% of capital gains, The fund term for Bio Bridge I is expected to be 6 years and 11 months
| Item | Details |
|---|---|
| Plan assumptions | Management fee rates vary by fund, but are generally around 2% per year, Performance fees are generally around 20% of capital gains, The fund term for Bio Bridge I is expected to be 6 years and 11 months |
| Key initiatives | Ongoing formation of Fund II and Fund III and expansion of the investment platform, Selection of investment opportunities ahead of the full-scale launch of investment activities, Building collaboration with 18 US venture capital firms for joint investments, Due diligence on multiple investment opportunities, We are working diligently toward executing investments |
| Publication date | 5 June 2026 |
Items this document does not state (22)
Plan namePlan periodProgress against the planSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsResults under the previous planReason for revision or withdrawalSize of the Target MarketRisks identifiedDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The NBI business differs from the conventional drug discovery business in terms of its revenue structure and the time required to generate revenue, and there have been comments that its details are difficult to understand. The explanation was therefore provided as part of the Company’s information disclosure to shareholders and investors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.